Cart
sales@molnova.com
Home - Products - Cell Cycle/DNA Damage - CDK - LSN2839567

LSN2839567

CAS No. 1231930-57-6

LSN2839567( —— )

Catalog No. M32766 CAS No. 1231930-57-6

LSN2839567 (Abemaciclib metabolite M2) is the active metabolite of Abemaciclib, a potent CDK4 and CDK6 inhibitor (IC50s: 1-3 nM) with anticancer activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 117 In Stock
10MG 188 In Stock
25MG 417 In Stock
50MG 601 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    LSN2839567
  • Note
    Research use only, not for human use.
  • Brief Description
    LSN2839567 (Abemaciclib metabolite M2) is the active metabolite of Abemaciclib, a potent CDK4 and CDK6 inhibitor (IC50s: 1-3 nM) with anticancer activity.
  • Description
    Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s of 1.2 and 1.3 nM, respectively. Anti-cancer activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1231930-57-6
  • Formula Weight
    478.54
  • Molecular Formula
    C25H28F2N8
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 2 mg/mL (4.18 mM; Ultrasonic )
  • SMILES
    CC(C)n1c(C)nc2c(F)cc(cc12)-c1nc(Nc2ccc(CN3CCNCC3)cn2)ncc1F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Teresa Burke, et al. Abstract 2830: The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6. Cancer Research. July 2016, 76 (14).
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • TG003 B

    TG003 is a potent Clk1/Sty inhibitor that inhibits Clk1 and Clk4, inhibits cancer cell growth and induces apoptosis, and can be used in the study of Duchenne muscular dystrophy.

  • CYC065

    CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.

  • Senexin C

    Senexin C is a novel orally active and specific CDK8/19 inhibitor with potential anticancer activity.Senexin C is more metabolically stable and potent than Senexin B. Senexin C inhibits the growth of MV4-11 leukaemia cells.

Sign In Join Free